https://www.trialsitenews.com/fda-approves-ind-for-celyds-car-t-cell-therapy-cyad-02-employing-horizons-optimized-smartvector-shrna-technology/Their trial starts early next year just as our OPMD trial does. Ours will change the course of history.
MKT The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint